Pharmacological control is a desirable safety feature of oncolytic adenoviruses (oAdV). It has recently been shown that oAdV replication may be controlled by drug-dependent transcriptional regulation of E1A expression. Here, we present a novel concept that relies on tamoxifen-dependent regulation of E1A activity through functional linkage to the mutated hormone-binding domain of the murine estrogen receptor (Mer). Four different E1A-Mer chimeras (ME, EM, E DNLS M, MEM) were constructed and inserted into the adenoviral genome under control of a lung-specific surfactant protein B promoter. The highest degree of regulation in vitro was seen for the corresponding oAdVs Ad.E DNLS M and Ad.MEM, which exhibited an up to 100-fold higher oAdV replication in the presence as compared with the absence of 4-OH-tamoxifen. Moreover, destruction of nontarget cells was six-and 13-fold reduced for Ad.E DNLS M and Ad.MEM, respectively, as compared with Ad.E. Further investigations supported tamoxifen-dependent regulation of Ad.E DNLS M and Ad.MEM in vivo. Induction of Ad.E DNLS M inhibited growth of H441 lung tumors as efficient as a control oAdV expressing E1A. E DNLS M and the MEM chimeras can be easily inserted into a single vector genome, which extends their application to existing oAdVs and strongly facilitates in vivo application.
Introduction
Oncolytic adenoviruses (oAdV) have become a promising tool for cancer gene therapy. After infection, they cause viro-oncolysis of tumor cells resulting in the release of newly generated virions, followed by infection of neighboring tumor cells, which leads to the destruction of further tumor mass. 1 oAdV replicate with high efficiency in cancer cells, whereas surrounding normal cells are protected against viral replication.
2 This has been achieved, for example, by insertion of mutations into the E1A or E1B gene to abolish the specific ability of the E1-region encoded proteins to deregulate the cell cycle proteins p53, p300 and pRB [3] [4] [5] [6] [7] [8] [9] or by insertion of tumor-or tissue-specific promoters into the adenoviral genome to drive the E1A, E1B or E4 gene, respectively. 4, 6, [10] [11] [12] [13] [14] [15] [16] Although oAdV are strongly attenuated in primary cells and from this point of view appear to be safe for use in humans, strong oAdV replication in the tumor can induce extensive tumor necrosis due to viro-oncolysis 17, 18 and an efflux of viral progeny into the blood stream 18, 19 leading to the induction of a strong systemic immune response, which may create serious side effects. In one phase II clinical trial, a cancer patient showed an abnormal immunological reaction and developed localized vascular leakage at the site of metastatic tumors in the chest following repetitive oAdV applications. 18 Therefore, additional safety features are desirable to further minimize the potential risks for humans. One promising approach appears to be the use of oAdVs, whose replication can be regulated pharmacologically, opening the possibility to control adenoviral replication temporally from the outside. To this end, it has been shown that adenoviral replication can be pharmacologically regulated via control of E1A gene expression by a mouse mammary tumor virus (MMTV) promoter, 20 by the rapamycin dimerization system, 21 by an optimized Tet-On gene expression system 22, 23 or through insertion of drug responsive elements into tumor-specific promoters.
complex of heat-shock proteins including hsp90, hsp70 and hsp56, most probably through direct interaction of hsp90 with the HBD. 27, 28 Binding of a functional ligand leads to an alteration in the structure of the HBD, which allows release of the chimera from hsp90, refolding to an active form and stabilization by dimerization of the HBD. 28, 29 Several intracellular proteins have been rendered functionally hormone-dependent by fusing them with steroid receptors, among them are several viral and cellular transcription factors like E1A, 26, 30 HIV Rev, 31 c-Myc 32 and v-Myb. 33 Previously it has been shown that fusion proteins of a mutated HBD of murine estrogen receptor (Mer) 34 or its human analogue (ER) 35 enable very tight regulation of the corresponding effector proteins in vitro and in vivo. [35] [36] [37] [38] While these mutated HBDs are unable to bind endogenous estrogen, their function can be modulated by the antiestrogen tamoxifen and its more potent derivative 4-OH-tamoxifen (4-OH- Tam) . 34, 35, 39 Tamoxifen is a relatively nontoxic compound used in palliative and adjuvant treatment of breast cancer and can be administered to the patients over a very long time period. 32, 35, 40 Here, we show that oAdV can be regulated in vitro and in vivo by tamoxifen-and 4-OH-Tam-dependent modulation of the activity of E1A-Mer chimeric proteins E DNLS M and MEM. The use of these E1A-Mer fusion proteins makes it easy to insert the drug-dependent regulatory components into one vector genome.
Results

Construction of E1A-Mer chimeras
For pharmacological regulation of oAdV replication, we used a mutated HBD of Mer, 34 which is unable to bind estradiol but retains its function in the presence of the antiestrogen tamoxifen or its more potent derivative 4-OH-Tam. 34, 39 This domain was fused to an adenoviral E1A protein containing a deletion in the pRB-binding site (amino acids 122-129 within CR-2 41 ) at either the N-terminus (ME) or C-terminus (EM) or at both the Nand C-terminus (MEM) (Figure 2a ). Based on a model describing the functional activation/inactivation of chimeric proteins containing the HBD of steroid receptors, 28 the E1A-Mer fusion proteins were assumed to promote viral gene expression and replication only in the presence of tamoxifen or 4-OH-Tam ( Figure 1 ).
4-OH-Tam does not influence E1A-Mer chimeras expression
To functionally characterize E1A-Mer chimeras, plasmidbased E1A-Mer expression constructs pAd.TRE.ME, pAd.TRE.MEM and pAd5.TRE.EM were transfected into HeLa cells. In these constructs, the E1A-Mer chimeras are driven by a tetracycline-responsive promoter (TRE), which was induced by transduction of cells with Ad5CMVrtTA-M2 (a replication-deficient adenovector (rdAdV) expressing a tetracycline-controlled reverse transactivator rtTA-M2 42 ) 24 h after transfection and further incubation in the presence of doxycycline (Dox). Cells were incubated for a further 24 h time period in the absence or presence of 4-OH-Tam and total RNA was isolated. The presence of 4-OH-Tam had virtually no influence on steady-state mRNA levels of all three E1A-Mer chimeras (Figure 2b) . In comparison to ME and EM, mRNA levels for MEM were slightly reduced, which may be due to changes in mRNA stability. These results clearly exclude major effects of 4-OH-Tam on E1A-Mer chimera expression at the transcriptional level.
Trans-complementation of adenoviral replication by E1A-Mer chimeras
One of the essential functions of E1A in adenoviral replication is the transactivation of other adenoviral promoters. 43 To examine whether the E1A-Mer chimeras could fulfil this function, the heterologous minimal CMV promoter (CMV min ) was used as a model system as has been described by us previously. 22 HeLa cells were cotransfected with the plasmid pAd5TREluc, which contains the luciferase gene under control of the CMV min and either pAd.TRE.ME, pAd.TRE.MEM or pAd. TRE.EM. For functional activation of E1A-Mer chimeras, 4-OH-Tam was added to final concentrations of 200 nM or 2 mM. Luciferase activities were determined 2 days after transfection. We found that all three E1A-Mer chimeras were able to transactivate the CMV min in a 4-OH-Tam-dependent manner. While the MEM (5.4-fold) and the EM fusion proteins (6.6-fold) showed similar regulation levels, the ME fusion protein had a higher basal activity in the absence of 4-OH-Tam, thus reducing (2.3-fold) the increase in activity in the presence of 4-OHTam ( Figure 2c) .
Next, we examined whether the E1A-Mer chimeras could also trans-complement adenoviral replication in a 4-OH-Tam-dependent manner. For these experiments, we chose the chimeric protein EM, which had shown the best level of regulation in the trans-activation assay. HeLa cells transfected with pAd.TRE.EM were transduced with Ad5CMVrtTA-M2 and incubated in the presence of Dox to induce E1-Mer chimera expression and additionally transduced with the E1A-deleted recombinant adenoviral reporter vector Ad5CMVluc as an indicator for adenoviral DNA replication. After addition of 4-OH-Tam, a 38-fold increase in the Ad5-CMVluc-DNA load was observed as compared with the absence of the inducer (Figure 2d ). Thus, EM can functionally replace E1A in adenoviral DNA replication. Interestingly, adenoviral replication in the absence of the 4-OH-Tam was only two-fold higher than in samples transfected with an irrelevant control plasmid, which indicates that EM has a low background activity in the noninduced state.
Subcellular localization of E1A-Mer chimeras
In line with its function as a transcriptional activator, 44, 45 E1A-13S is rapidly translocated into the nucleus by means of a strong nuclear localization signal (NLS) located at its C-terminus. 43 The HBD of estrogen receptor, on the other hand, is localized in the cytoplasm, where it interacts with hsp90 in the absence of ligand. 25 Since sequestration of different E1A-Mer chimeras in the cytoplasm in the absence of inducer represents one possible mechanism for their functional inactivation, we investigated their subcellular localization. HeLa cells were transfected with plasmids pAd.TRE.ME, pAd. TRE.MEM, pAd5.TRE.EM or pAd5TRE-E1A expressing the native E1A protein. E1A-Mer chimera expression was induced by cotransfection with pAd5CMVrtTA-M2 expressing the rtTA-M2 and addition of Dox. Subcellular
Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al localization of EM, MEM, EM or E1A was monitored 48 h post transfection by indirect immunofluorescence using an anti-E1A antibody. The native E1A protein and the ME and EM chimeras were exclusively localized in the nucleus both in the presence and absence of 4-OH-Tam ( Figure 3 ). The MEM chimera containing two Mer domains exhibited strictly nuclear localization in the presence of 4-OH-Tam, but, in addition to a predominant nuclear staining, it showed a clearly detectable level of cytoplasmic staining in the absence of 4-OH-Tam. These data demonstrate that native Mer is not able to sequester significant amounts of E1A in this compartment. The differential activity of the E1A-Mer chimeras in the presence versus the absence of the inducer, therefore, more likely depends on direct Mer-dependent modulation of E1A activity than on an altered subcellular localization.
E1A-Mer-mediated regulation of oncolytic adenovector replication
The promising results presented in the previous section led us to construct adenoviral vectors Ad.ME, Ad.MEM and Ad.EM harboring the three different E1A-Mer chimeras (Figure 4a ). In order to further enhance the specificity of these oAdV, the E1A-Mer proteins were placed under transcriptional control of an SP-B promoter, which can restrict oAdV replication to lung carcinomas. 6 We first analyzed E1A-Mer mRNA expression levels after infection of H441 lung carcinoma cells with either the E1A-Mer adenoviral vectors or the analogous vector Ad.E containing the native E1A protein 22 at an MOI of 4. Cells were incubated either in the presence or absence of 4-OH-Tam and monitored for E1A mRNA expression levels 24 h post infection. For the adenoviral vectors harboring the E1A-Mer chimeras, mRNA levels were highly 4-OH-Tam-dependent, whereas those of the control vector Ad.E were not (Figure 4b ). In contrast to ME-and MEM-mRNAs, which were detectable only in the presence of 4-OH-Tam, a basal level of EM-mRNA could also be detected without induction. In the presence of inducer, however, EM-mRNA levels were also strongly increased and even exceeded those of the E1A-13S mRNA expressed by Ad.E. Since regulation of gene expression from oAdV involves both transcriptional mechanisms and adenoviral DNA replication, these results already indicated 4-OH-Tam-dependent E1A-Mer-mediated adenoviral replication.
To directly monitor adenoviral replication, infectious titers of progeny virus for Ad.ME, Ad.MEM and Ad.EM, both in the absence and presence of inducer, were determined in a 72 h time-course experiment by standard plaque assays on 293 cells. The highest degree of regulation was observed for Ad.MEM with a 50 and 92.5 times higher progeny production in the presence of 4-OH-Tam 48 and 72 h after infection, respectively (Figure 4c ). This vector also showed the lowest background replication in the absence of 4-OH-Tam. Compared with Ad.ME or Ad.EM, Ad.MEM titers were four times lower 24 h after infection and 1.2 or 38 times lower, Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al respectively, at 72 h post infection. Ad.ME exhibited reduced susceptibility to 4-OH-Tam (11.3-fold higher virus titers in the presence of 4-OH-Tam 48 h post infection), which was accompanied by a progeny production 10 times lower than that found for Ad.MEM in the presence of 4-OH-Tam (Figure 4c ). Although Ad.EM showed slightly reduced regulation compared with Ad.MEM (41-fold after 48 h), the absolute levels of progeny virus in the presence of 4-OH-Tam were about 10 times higher. In the presence of the inducer, Ad.EM showed stronger replication than the original Ad.E without Mer sequences (results not shown) making it an ideal candidate for further investigation. Ad.E showed similar replication rates in the presence and 
Deletion of the NLS in the EM chimera increases 4-OH-Tam-dependent regulation of adenoviral replication
Previously it has been shown that an E1A protein deleted in its NLS 12 is functional for adenoviral replication but moves to the nucleus much more slowly. 46 This suggested that deletion of the NLS in EM might be an effective mean to sequester the mutated protein in the cytoplasm in the absence of inducer and thereby reduce leakiness. Transfection experiments with the corresponding plasmid pAd.E DNLS M in HeLa cells confirmed an enhanced cytoplasmic retention of E DNLS M in the absence of 4-OH-Tam and a less pronounced nuclear accumulation in its presence as compared with EM ( Figure 5 , compare to Figure 3) . Removal of the E1A-NLS from the MEM chimera even led to a complete cytoplasmic retention of the protein in the absence of 4-OH-Tam ( Figure 5 , ME DNLS M). To investigate E DNLS M-dependent adenoviral replication, we infected H441 cells with Ad.E DNLS M in the presence or absence of 4-OH-Tam and compared the titers of progeny virus to those of Ad.EM and Ad.E. In comparison to the parental construct Ad.EM, Ad.E DNLS M showed a 14-fold reduced viral replication in the absence of 4-OH-Tam and a twofold increase in 4-OH-Tam-dependent regulation of adenoviral replication. This resulted in absolute replication rates in the presence of 4-OH-Tam that were only 2-4 times lower than for Ad.E (Figure 4d ), but quite similar to the values obtained with Ad.MEM (compare Figure 4c ). Ad.E showed no significant differences in replication in the presence and absence of 4-OH-Tam (Figure 4d ). These results indicated that deletion of NLS of E1A in the EM chimera is a useful method to reduce leakiness and increase tamoxifen-mediated regulation of an oAdV harboring the chimeric protein.
4-OH-Tam-dependent regulation of E1A-Mer adenovirus-mediated cytotoxicity
To assess the oncolytic potential of the different viruses, we infected H441 cells with Ad.ME, Ad.MEM, Ad.EM, Ad.E DNLS M or the control vector Ad.E at an MOI of 10. Cells were incubated either in the absence or presence of 4-OH-Tam and cell-killing activity was monitored by staining viable cells with crystal violet. The cytolytic effects of E1A-Mer adenoviruses on H441 cells largely correlated with their ability to replicate. Ad.MEM and Ad.E DNLS M, were both strongly attenuated in the absence of 4-OH-Tam, but exhibited potent killing activity in its presence. However, they were less efficient than the control Ad.E ( Figure 6 ). In contrast, in the presence of 4-OH-Tam, Ad.EM eradicated tumor cells more effectively than Ad.E, but some residual cell-killing activity was also observed in its absence. Limited attenuation in the absence of the inducer and no clear increase of cytolytic activity in its presence were the hallmarks of Ad.ME, excluding it as potential candidate for in vivo studies.
Tumor cell-specific replication of 4-OH-Tam-dependent oAdVs
To examine the tumor specificity of Ad.ME, Ad.MEM, Ad.EM, Ad.E DNLS M, their replication in H441 lung carcinoma cells (in which the endogenous SP-B promoter is active) was compared with that in EA.hy.926 cells (in which the endogenous SP-B promoter is not active). Both cell lines were infected at an MOI of 5 and Ad.E was included as a control. Replication was monitored by Southern blot hybridization of DNA isolated 24 h post infection. The amount of replicated adenoviral DNA of all E1A-Mer-dependent oAdVs under induced conditions, but also of the 4-OH-Tam-independent control Ad.E, was clearly higher in H441 than in EA.hy.926 cells, which indicates the specificity of the SP-B promoterdependent oAdV replication. With the exception of Ad.EM in the presence of the inducer, replication of the 4-OH-Tam-dependent oAdVs was barely detectable in EA.hy926 cells. Moreover, despite similar replication rates in H441 cells, Ad.E DNLS M replication was reduced six-fold and Ad.MEM even 13-fold as compared with Ad.E in nontarget EA.hy926 cells (Figure 7 ). These results show that both, MEM and E DNLS M, not only Figure 3 Subcellular localization of E1A-Mer chimeras. HeLa cells were cotransfected with the plasmid pAd5CMVrtTA-M2 expressing the rtTA-M2 and either pAd.TRE.ME, pAd.TRE.MEM, pAd5. TRE.EM or pAd5TRE-E1A expressing the native E1A protein. E1A-Mer chimera expression was induced by adding Dox to a final concentration of 1.5 mg/ml in all samples, and, where indicated, 4-OH-Tam was added to a final concentration of 10 mM. Detection of EM, MEM, EM and E1A was carried out 48 h after transfection using rabbit-anti-E1A antibody as a primary antibody, donkey antirabbit biotin-labeled antibody as a secondary antibody and streptavidin coupled Cy3 for visualization. Nuclear staining was carried out with Dapi. Cytoplasmic staining of MEM chimera is indicated by arrows.
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4-OH-Tam-dependent regulation of Ad.MEM replication in vivo
To determine the tamoxifen-dependent regulation levels and therapeutic efficacies of E1A-Mer adenoviruses in vivo, the adenovectors Ad.MEM and Ad.E DNLS M, which had shown the best regulation levels in vitro, were used for an H441 xenograft model in nude mice. Mice bearing established subcutaneous H441 tumors were injected with 5 Â 10 7 plaques forming units (PFU) of Ad.MEM or replication-deficient control AdV Ad5TRE-luc. Ad.MEM replication was induced by daily intraperitoneal application of 4-OH-Tam or tamoxifen. After 5 days, tumor tissues were assayed for infectious virions. Ad.MEM virus titers were 31 times higher in the presence of inducers than in their absence (P ¼ 0.058) and were significantly increased (Po0.005) compared with the Ad5TREluc control group (Figure 8a) . No significant differences were seen between Ad.MEM in the absence of inducers and Ad5TREluc.
To assess the in vivo oncolytic activities of E1A-Merdependent adenoviruses, H441 subcutaneous tumors were established in nude mice and injected twice at a 3-day interval with 3.4 Â 10 7 PFU of Ad.E DNLS M, the replication-deficient Ad5TREluc or the replication-competent Ad.E. Ad.E DNLS M replication was induced by intraperitoneal application of tamoxifen three times a week. Tumor growth in the Ad5TREluc-infected control group was comparable in the presence and absence of tamoxifen, excluding direct effects of tamoxifen on tumor growth. Compared with Ad5TREluc, Ad.E DNLS M and Ad.E inhibited tumor growth significantly (Po0.02 for both) in the presence of tamoxifen, while Ad.E DNLS M caused only slight inhibition in the absence of tamoxifen (Figure 8b ). Thus, levels of oncolytic activity similar to those with unmodified E1A adenoviruses can be achieved with Ad.E DNLS M virus in vivo.
Discussion
Pharmacological regulation is a desirable property of oAdVs to increase their safety for use in human cancer gene therapy. Meanwhile, several systems have been tested for their usability to regulate oAdV replication. All of them are based on the regulation of E1A gene expression, either through the use of promoters directly Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al dependent on certain drugs for their activity 20 or the use of different combinations of drug-dependent transcriptional transactivator (TA) and/or silencer (TS) proteins with their corresponding responsive elements. [21] [22] [23] In their present form, 10,24 these oAdVs have several disadvantages. An MMTV promoter-dependent oAdV, for example, requires dexamethasone for drug-dependent activation of E1A expression. 20 Dexamethasone affects the metabolism of many organs, which makes it difficult to use it in clinical applications. Recently, we have used the Tet-On system 22, 23 and other investigators have turned to the rapamycin-dependent dimerizer gene expression system 21 for control of oAdV replication. Presently, however, these oAdVs require one or two additional vectors expressing the drug-dependent transcriptional regulators. Whereas it may be possible to integrate the essential regulatory components into a single vector genome, several disadvantages remain. Owing to the insertion of multiple transcriptional regulators and cis-acting regulatory DNA sequences, much space is lost in the vector genome for other functional components like tumor suppressor or cytotoxic genes, which have become a powerful new tool for enhancing the tumor destructive efficiency of oAdVs. 47 Furthermore, inducible promoters can become leaky if not separated from the E1A enhancer 22 and, most importantly, the adaptation of such systems to existing oAdVs may be very complicated.
More than 10 years ago it was shown that the function of chimeras of the adenoviral E1A protein with the HBD of the human estrogen receptor can be regulated in an estrogen-dependent manner. 30 This finding prompted us to investigate whether the replication of oAdVs, which involves a whole series of tightly regulated substeps, can also be regulated by such E1A chimeras. In order to Tumor-specific replication of 4-OH-Tam-dependent oAdV. H441 lung carcinoma cells (with endogenous SP-B promoter activity) and EA.hy.926 cells (without endogenous SP-B promoter activity) were infected with the indicated adenovectors at an MOI of 5. After 24 h, DNA was isolated, digested with HindIII and subjected to Southern blot analysis with a mix of E1A-specific sense and antisense probes. Note: a HindIII site is located at the 5 0 end of the bGH-polyA termination signal in all vector constructs, so that hybridizing DNA bands represent the 5 0 located parts of the corresponding vectors, which differ in size. Blots rehybridized with a b-actin probe confirmed equal DNA loading (not shown).
Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al prevent the interaction of the HBD with endogenous estrogen, aimed at reducing possible side effects in vivo, we fused E1A to a mutated Mer. Mer is unable to bind estrogen, but has a high affinity for tamoxifen or its more potent derivative 4-OH-Tam. 34 The tight regulation of such chimeras seems to be strongly dependent on the fusion site of the HBD on the effector protein. 38 We therefore used several different variants of E1A-Mer fusion proteins in order to evaluate their suitability for regulation of oAdVs. Our initial investigations with the isolated E1A-Mer chimeras clearly documented that their function could be modulated by 4-OH-Tam and that they could fulfil the complex functions of the native E1A in the transactivation of viral promoters-and trans-complementation of adenoviral replication.
The mechanisms, by which the function of HBD fusion proteins is regulated, are not completely understood. However, a critical factor is the binding of the HBD to hsp90 in the absence of ligand, which results in functional inactivation of the fusion protein. After binding of the ligand to the HBD, the fusion protein is released from this complex. 28 This mechanism seems to be very efficient. It was shown that E1A fused to the HBD of the glucocorticoid receptor is fully hormonedependent for adenoviral E3 promoter stimulation, although the fusion protein is located exclusively in the nucleus even in the absence of the inducer. 26 This finding is in line with our results obtained for the three initial E1A-Mer chimeras, which still contain the E1A-NLS, and are also hormone-dependent despite their efficient translocation into the nucleus in the absence of ligand. However, all these three constructs induced some level of oAdV replication in the absence of 4-OH-Tam. In an attempt to inhibit rapid nuclear transfer 43 and thereby reduce leakiness of the E1A-Mer fusion proteins in the absence of inducer, we deleted the E1A NLS in the most efficient, but at the same time also most leaky fusion variant EM. This led to a 14-fold reduction of leakiness and two-fold enhanced regulation of oAdV replication as compared with the parental protein, which was accompanied by an enhanced cytoplasmic sequestration in the absence of the inducer. A low leakiness and high regulation levels were also observed for the adenovirus with the MEM chimera, which also showed some retention in the cytoplasm. Thus, measures aimed at promoting the cytoplasmic accumulation of the respective fusion protein may present a more general possibility to enhance the level of regulation of Mer fusion proteins. However, in addition to an enhanced cytoplasmic sequestration as one potential mechanism explaining the reduced leakiness of E DNLS M and MEM in the absence of the inducer, other possible explanations have also to be taken into account. One of these is based on the so called model of space-dependent repression of the effector protein by the HBD, which was originally promoted by the finding that the efficiency of repression Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al of an fused effector protein by HBD in the absence of ligand decreases as the size of the fusion protein increases. 26 E1A has three important functional domains, which are conserved among different adenovirus subtypes. Conserved regions 1 and 2 (CR1 and CR2) are located in the N-terminal part of the protein, while the CR3 domain is located at the C-terminus. 48 Possibly, these three functional E1A domains are not completely suppressed after fusion of Mer to either N-or C-terminus of E1A, leading to the observed residual activity of these E1A-Mer chimeras. Either the reduction of the absolute size of the effector gene as in E DNLS M or an increase in the ratio of the size of the Mer domain(s) relative to the E1A protein by addition of a second Mer domain as in MEM may lead to an abrogation of the space limitation for Mer suppression and increase the tightness of the E1A-Mer chimera in the absence of the inducer. In addition to the relative size of the E1A protein and the Mer domain(s), the site of fusion of Mer to E1A also plays an important role for the function of the E1A-Mer chimeras as revealed by the striking differences between the EM and the ME chimeras. The oAdV harboring the EM chimera was absolutely superior to that harboring the ME chimera in terms of absolute replication levels and pharmacological regulation. Whereas Ad.ME clearly did not fulfil the requirements for a regulated, highly active oAdV, Ad.EM displayed several features making it interesting for potential in vivo application. Although Ad.EM showed the highest replication rate of the three original E1A-Mer adenoviruses (without further modification of the E1A moiety) in the absence of inducer, it still could be induced more than 50-fold by 4-OH-Tam, resulting in an even two-fold higher replication rate than the control Ad.E. This represents a very interesting finding, since it shows the feasibility of increasing oAdV replication by genetically engineering the properties of E1A. The molecular basis for this phenomenon, however, is not quite clear. It may be speculated that the liganddependent transactivation domain present in Mer or the ability of Mer to form protein dimers 27 may be involved in enhancing EM function.
As discussed above, regulation levels of E1A-Mer chimeras could be further enhanced by deletion of the NLS in EM, although at the cost of a decrease in the absolute viral replication levels. However, the absolute amounts of newly generated progeny virus of Ad.E DNLS M were still in the range of that of the control oAdV. Similar observations were made for the Ad.MEM virus with two Mer domains. Regulation levels for this virus variant could be further enhanced by raising the 4-OH-Tam concentration to 10 mM resulting in a 930-fold difference in viral replication between the noninduced and the induced state. Whereas increasing the doses of the inducer is feasible in vitro, this approach may create severe problems in vivo due to increased drug-mediated side effects. One possible solution would be drugs with a higher binding activity for the Mer domain, which we are planning to test in the near future. Another way to improve regulation of E1A-Mer vectors is the coexpression of the tetracycline-controlled transcriptional silencer (tTS), 49 which can further reduce the leakiness of the vectors by suppression of the SP-B promotor. 22 This opens the perspective to combine two different systems (Tet-On and tamoxifen-system) as an option to further improve oAdVs.
The E1A-Mer-dependent oAdVs showed a variable 4-OH-Tam-dependent viro-oncolytic potential in vitro that closely reflected differences in regulation of 4-OHTam-dependent oAdV replication. Cells infected with Ad.MEM and Ad.E DNLS M were highly protected in the absence of 4-OH-Tam, whereas they were lysed in its presence. However, their viro-oncolytic potential in the presence of 4-OH-Tam was lower than that of Ad.EM. Of note, this virus even killed cancer cells more efficiently than the control Ad.E.
One of the most important requirements for the in vivo application of oAdVs is a highly tumor cell specific replication. The vectors presented in this study possess several features to comply with this requirement, which include a deletion of the E1A pRB-binding site 41 in the chimeras, a deletion of the E1B region 50 and, most importantly, a lung-specific SP-B promoter, which drives the expression of the E1A-Mer chimeras. However, if the SP-B promotor is inserted into the E1A region of our AdV backbone it becomes slightly leaky in nontarget cells as demonstrated by us recently. 22 For Ad.EM, the basal EM expression could be sufficient to mediate adenoviral replication in nontarget EA.hy926 cells creating an autoactivatory feedback loop. In contrast, MEM and E DNLS M show a lower replication level than Ad.EM in H441 cells, which may be below the threshold level needed to promote this autoactivation loop in EA.hy926 cells. In line with this hypothesis, the replication of Ad.MEM and Ad.E DNLS M in cells without SP-B promoter activity was nearly undetectable even in the presence of the inducer as opposed to the control vector Ad.E, whereas at least for Ad.E DNLS M, replication in permissive cells was comparable to that of Ad.E. The resulting enhancement of specificity for lung tumor cells of 13-fold and six-fold, respectively, for Ad.MEM and Ad.E DNLS M as compared with Ad.E clearly indicates that the E1A chimeras can efficiently contribute to a reduction in the leakiness of oAdVs.
The in vivo studies demonstrated significant replication and inhibition of tumor growth for Ad.MEM and Ad.E DNLS M in the presence of tamoxifen if compared with replication-deficient control AdV Ad5TREluc. Moreover, tamoxifen-induced Ad.E DNLS M was as efficient as the replication-competent control vector Ad.E in inhibition of tumor growth. These data clearly indicate the efficiency of Ad.MEM and Ad.E DNLS M after induction with tamoxifen. Despite the fact that there was a clear tendency (P ¼ 0.058) in tamoxifen-dependent regulation of vector replication in vivo, there were no significant differences in Ad.MEM replication or in Ad.E DNLS M reduction of tumor growth in the presence versus absence of tamoxifen. A main factor contributing to the lack of significance was the high background levels in the absence of tamoxifen in some of the animals. The reasons for these high background levels may be very complex, but it can almost be excluded that they were due to strong nonspecific vector replication in these animals, since both vectors were nearly completely silent under uninduced conditions in vitro. Other factors, namely the variance in individual animals and the relative low number of tumors investigated, may therefore present the main reasons for the lack of significancy. A low efficacy of tamoxifen in the short time in vivo experiments with Ad.MEM could also be an factor, since tamoxifen enables lower vector replication in vitro than 4-OH-Tam (results not shown).
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We did not investigate Ad.MEM and Ad.E DNLS M replication in cells without SP-B promotor activity in vivo. However, it has been shown that an oAdV containing the same promoter construct to drive the adenoviral E4 protein was attenuated in cells without SP-B promotor activity. 6 Our own data support similar behavior for Ad.MEM and Ad.E DNLS M since both vectors were strongly attenuated in nontarget cells in vitro.
Tamoxifen is used in the treatment of breast cancer of woman but can also be used in men. In contrast to other chemotherapeutic agents it lacks severe toxicity, also after long-term administration, and even exhibits beneficial effects against osteoporosis and coronary vasculare disease. 51, 52 The tamoxifen doses used in the in vivo experiments were 3-6 times below the toxic doses in mice and we did not find toxicity in mice. The doses of tamoxifen that can be used for a long-term therapy in humans is 40 mg/day and are below the levels of tamoxifen used by us in mice. However, lower doses of the drug do not necessarily have to lead to a reduction of efficacy of the E1A-Mer vectors in vivo. A major disadvantage of tamoxifen in the regulation of E1A-Merdependent oAdVs is its relative long in vivo half-life of 7 days, which may compromise a rapid shut off of the adenoviral vectors after withdrawal of the drug. In line with this argumentation, we found that application of 4-OH-Tam to the cell culture and withdrawal 24 h later did not result in shut off of Ad.MEM replication during a further 72 h incubation period (results not shown). Other selective estrogene receptor modulators, for example, droloxifen, which has a half life of only 27 h 53 and a 10-fold higher binding affinity for the estrogene receptor 54 than tamoxifen, may therefore be more suitable for these in vivo applications.
In summary, this study focused on the analysis of tamoxifen-regulated E1A-Mer chimeras for pharmacological control of oAdV replication in vitro and in vivo. Our results clearly demonstrate that E1A-Mer chimeras retain the very complex functions described for E1A. 48 They also demonstrate for the first time that oAdV replication can be efficiently regulated by pharmacological modulation of E1A activity. Furthermore, compared with gene expression systems previously examined for control of oAdVs. [21] [22] [23] E1A-Mer chimeras simplify the construction of pharmacologically regulated oAdVs. The two E1A-Mer variants MEM and E DNLS M best fulfil the requirements of tightly regulated effector proteins for adenoviral replication and oncolytic activity. For in vivo applications, E DNLS M seems to better suited than MEM, because it mediates a stronger oAdV replication in the presence of the inducer, and the presence of only one Mer domain minimizes the risk of recombination. In addition, the small size of the E DNLS M cDNA of only 1650 bp makes it possible to substitute the adenoviral E1A protein without a substantial increase in vector size, so that E DNLS M can easily be inserted into a single vector genome and adapted to all currently available oAdVs.
Materials and methods
Cell lines
The following cell lines were used for investigations: HeLa (human cervical carcinoma) cells and HEK293 (human embryonal kidney) cells were cultured in DMEM (Gibco BRL). H441 (human pulmonary adenocarcinoma) cells 55 (kindly supplied by JA Whitsett, Children's Hospital Medical Center, Cincinnati, OH, USA) were cultured in RPMI 1640 medium supplemented with 2 mM glutamine. EA.hy926 cells (a hybrid cell line from HUVEC and A549 56 ) were cultured in DMEM supplemented with HAT. All media were supplemented with 10% FCS and 1% of each penicillin and streptomycin.
Plasmids construction
Three different E1A-Mer fusions proteins were constructed. The mutated HBD of the Mer 34 was amplified from the plasmid pANMerCreMer 38 (kindly supplied by M Reth, Department of Molecular Immunobiology, MaxPlanck-Institute for Immunobiology, University of Freiburg, Germany) with two primer pairs generating either BamHI/NheI or NheI/HindIII restriction sites at the ends of the amplified sequence and one or two different copies of the amplified Mer sequences were then inserted into BamHI/NheI-or NheI/HindIII-digested plasmid pAd5-TREluc 23 to generate pAd.TRE-Mer1 or pAd.TRE-Mer1-Mer2, respectively. The primer pairs were as follows: 5 0 -TAC GGA TCC TGC CTG CAC ACC ATG GGA GAT-3 0 / 5 0 -CTA GCT AGC TTA GTC GAC GAT CGT GTT GGG GAA GCC-3 0 and 5 0 -CCA GCT AGC GGT TCT GGA GAT CCA CGA AAT GAA ATG GGT GC-3 0 /5 0 -CAG AAG CTT TCA GAT CGT GTT GGG GAA GCC-3 0 . For generation of pAd.TRE.MEM encoding a Mer-E1A-Mer fusion protein, the E1A DpRB -cDNA was amplified from pAd5TetO 7 SPB-E1A DpRB 22 with primers 5 0 -GAT CGT CGA CCT GCA GAC CAT GAG ACA TAT TAT CTG CCA CGG-3 0 (termed: E1s) and 5 0 -ACC GCT AGC TGG CCT GGG GCG TTT ACA GCT C-3 0 and inserted in frame between the two Mer sequences of pAd.TREMer1-Mer2 via SalI/NheI. The plasmid pAd.TRE.ME encoding a fusion protein of Mer with the N-terminus of E1A was constructed by insertion of the E1A DpRB -cDNA after amplification with the primers E1s and 5 0 -CGC GCT AGC TTA TGG CCT GGG GCG TT-3 0 into pAd.TREMer1 via SalI/NheI. The plasmid pAd.TRE.EM encoding a fusion protein of Mer with the C-terminus of E1A was generated by digestion of pAd.TRE.MEM with BamHI/ SalI, fill-in of the 5 0 overhangs with T4 polymerase and religation. For construction of adenoviral shuttle plasmids, the unique XbaI site in the plasmid pAd5TetO 7 SPBluc 22 was replaced by a unique SpeI site. To this purpose, a PCR fragment generated from pAd5TRE-E1A 23 with the primer pair 5 0 -CGG GGA TCC AAT GAG ACA TAT TAT CT-3 0 and 5-ATA AGA TCT ACT AGT CCC CAG CTG GTT CTT TCC-3 0 as a template was inserted into the HindIII/BglII-digested plasmid pAd5TetO 7 SPB-luc. Bam-HI/HindIII fragments from pAd.TRE.MEM or pAd. TRE.ME containing the MEM or the ME fusion protein were inserted into the BamHI/HindIII restriction sites of the intermediate construct to generate pAd.MEM and pAd.ME, respectively. The plasmid pAd.EM containing the EM chimera was generated by digestion of pAd. MEM with BamHI/SalI, fill-in of the 5 0 overhangs with T4 polymerase and religation. The E1A nuclear localization signal in plasmid pAd.MEM was deleted by amplification of a corresponding 670 bp fragment from pAd.MEM with primers E1s and 5 0 -CTA GCT AGC GCA TTC TCT GGA CAC AGG TG-3 0 and religation with SalI/NheI-digested pAd.MEM. The resulting construct Tamoxifen-dependent control of oncolytic adenovirus replication I Sipo et al pAd.ME DNLS M was then digested with BamHI/SalI and religated after fill-in of the 5 0 overhangs with T4 polymerase to generate pAd.E DNLS M. The plasmids pAd5TRE-E1A 23 and pAd5TRE-iGFP 22 have been described.
Construction of adenoviral vectors
The adenoviral shuttle plasmids pAd.MEM, pAd.ME, pAd.EM and pAd.E DNLS M were linearized with SpeI, ligated to the 5 0 long arm of XbaI-digested E1-E3-adenovirus mutant RR5, transfected into HEK293 cells and propagated as described 57 generating the adenoviral vectors termed Ad.ME, Ad.MEM, Ad.EM, and Ad.E DNLS M, respectively. The adenoviral vectors Ad5-CMVrtTA-M2, Ad5CMVluc, Ad5TREluc 23 and Ad.E (denoted earlier as Ad5TetO 7 SPB-E1A DpRB ) 22 have been described. All adenoviral constructs were tested for RCA contamination by PCR as described before 58 and the viral titers were determined using standard plaque assays on HEK293 cell.
Transfection experiments
Plasmid transfection was carried out with a calcium phosphate transfection kit (Stratagene). Cells were seeded in 12-well plates at a density of 2 Â 10 5 cells/ well or in 60 mm cell culture dishes at 5 Â 10 5 cells/dish and transfected with 2 mg plasmid/well in the presence of DMEM containing 10% FCS. After 18 h, cells were washed three times with PBS and fresh medium was added.
Northern blot analysis
Total RNA (10 mg) were separated on a 1% formaldehyde agarose gel and transferred to a Hybond N nylon membrane (Amersham). After prehybridization, the membranes were hybridized with a [ 32 P]dCTP-labeled ss-antisense E1A-DNA probe in ExpressHyb Solution (Clontech) following the manufacturer's instructions. Rehybridization for standardization of E1A-mRNA expression levels was carried out with a [ 32 P]dCTP-labeled ss-antisense b-actin-DNA probe. Labeling of probes was performed by PCR-like reactions as described previously. 59 Hybridized filters were exposed to Kodak Biomax MS film (Integra Biosciences).
Southern blot analysis
For detection of E1A-Mer-dependent adenoviral replication, DNA was isolated from vector-infected cells using an E.Z.N.A. Tissue DNA mini Kit (Peqlab Biotechnologie GmbH, Germany) 24 h after infection. HindIII-digested genomic/vector DNA mix (10 mg) was electrophoretically fractionated on a 1% agarose gel. After transfer to a Hybond N nylon membrane (Amersham), the membranes were hybridized with [
32 P]dCTP-labeled 657 nt ss-antisense and 852 nt ss-sense E1A-specific DNA probes. The labeling of ss-antisense and ss-sense E1A-DNA probes was carried out in a PCR-like reaction as described previously 59 using a E1A DpRB -cDNA fragment as template. Rehybridization for control of equal DNA transfer was carried out with a [ 
Luciferase assay
Luciferase assays were performed using the luciferase reporter gene assay Kit (Roche) following the manufacturer's instructions. Briefly, cells were washed twice with PBS buffer and lysed directly by adding 250 ml of cell lysis reagent and incubating for 15 min at room temperature. Cell debris was pelleted in a microfuge at maximum speed for 15 s and 10 ml of the supernatant was then transferred to a 5 ml tube (Sarstedt). Luciferase substrate (50 ml) was added and the luciferase activity was immediately measured in a Lumat LB 9501 luminometer (Berthold).
Indirect immunofluorescence
HeLa cells grown in 35 mm cell culture dishes and transfected with the indicated plasmids were fixed and permeabilized with 1 ml of TBS solution containing 4% formaldehyde and 0.5% Triton X 100. After blocking in TBS buffer with 5% donkey serum and 0.1% Triton X100, cells were incubated with anti-E1A rabbit polyclonal antibody Ad2 E1A (Santa Cruz Biotechnology) diluted 1:200 in blocking solution for 1 h. After rinsing, the cells were incubated with a biotin-labeled donkey anti-rabbit secondary antibody (Dianova) at a dilution 1:400 for 45 min. Cells were subsequently incubated with Cy3-conjugated streptavidin (Dianova) (dilution 1:500) for 30 min. Cell nuclei were stained by adding of 100 ml of DAPI (0.5 mg/ml) (Sigma) and cover slips were mounted using Fluoromount-Gt (Southern Biotechnology Assiates, Inc.). Fluorescence images were taken using an Olympus BX60 immunofluorescence microscope (Olympus). As controls, nontransfected HeLa cells were stained using the same protocol.
Semiquantitative PCR
Detection of Ad5TREluc DNA replication was carried out by competitive PCR as described previously. 58 Briefly, genomic plus episomal vector DNA were isolated by using the E.Z.N.A.
s Tissue DNA Kit II (Peqlab Biotechnologie GmbH). Ad5TREluc DNA and shortened luciferase internal standard DNA was amplified in 14-19 PCR cycles. For internal control, cellular genomic GAPDH and shortened GAPDH internal standard-DNA were amplified by 23-26 PCR cycles. The fluorescence-labeled amplification products were detected by capillary electrophoresis on an ABI 310 Genetic Analyzer (Applied Biosystems) and the amount of Ad5CMVluc DNA was calculated as described. 59 
Virus replication assay
Isolation of infectious virions from tumors was achieved by homogenizing the tumors in 1 ml DMEM medium using an Ultra Turrax homogenizer (IKA Labortechnik) followed by three freeze-thaw cycles. For release of virus from cultured cells, infected cells were scraped in 1 ml DMEM and frozen and thawed three times. The cellular debris was pelleted by centrifugation and the supernatant was used for reinfection of HEK293 cells. At 2 h post infection, cells were washed and overlaid with 1.25% low melting agarose dissolved in DMEM growth medium supplemented with 5% FCS. The PFU were counted 2-3 weeks later.
